Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Cingulate Inc (CING) Stock Price & Analysis

452 Followers

CING Stock Chart & Stats

$4.24-$0.32(-7.02%)
At close: 4:00 PM EST
$4.5$5$5.5Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$4.22 - $4.57
52-Week Range
$3.16 - $11.89
Previous Close
$4.56
Volume
N/A
Average Volume (3M)
116.09K
Market Cap
$68.64M
Enterprise Value
$50.02M
Total Cash (Recent Filing)
$28.40M
Total Debt (Recent Filing)
$6.29M
Price to Earnings (P/E)
―
Beta
0.24
Next Earnings
Nov 18, 2026 (Est.)
EPS Estimate
-0.43
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Drug Delivery

The proprietary delivery approach is designed to improve how ADHD medicines release over the day, supporting once-daily oral candidates. If clinical and regulatory objectives are achieved, this platform could differentiate products and provide a reusable foundation across related disorders.

Intellectual Property Protection

Issuance of a U.S. patent strengthens protection around CTx-1301 and can extend the period during which the company may defend its candidate from direct competition. This improves the potential commercial durability of the lead program if development succeeds.

Improving Shareholders' Equity

The move from negative equity in 2023 to positive equity in 2024 and 2025 represents a constructive balance-sheet trend. Although the company remains financially weak, maintaining positive equity provides a stronger base for funding development than the earlier deficit position.

Bears Say

No Revenue And Persistent Losses

Cingulate has not yet generated revenue and continues to report operating and net losses, indicating that its pipeline has not reached a commercial stage. The widening 2025 net loss increases the funding required to advance programs and delays any internally generated earnings base.

Persistent Cash Burn

Negative operating and free cash flow throughout the periods shown means Cingulate is consuming cash to fund operations rather than self-financing development. Continued annual burn can reduce financial flexibility and make future progress dependent on additional capital.

Regulatory Development Delay

The FDA Complete Response Letter delays progress for the lead ADHD candidate and indicates that chemistry, manufacturing, and controls issues must be addressed before advancement. This can extend development timelines, increase costs, and postpone potential commercialization.

Cingulate Inc News

CING FAQ

What was Cingulate Inc’s price range in the past 12 months?
Cingulate Inc lowest stock price was $3.16 and its highest was $11.89 in the past 12 months.
What is Cingulate Inc’s market cap?
Cingulate Inc’s market cap is $68.64M.
When is Cingulate Inc’s upcoming earnings report date?
Cingulate Inc’s next earnings report is estimated for Nov 18, 2026 (not yet confirmed), which is in 12 days.
How were Cingulate Inc’s earnings last quarter?
Cingulate Inc released its earnings results on Aug 13, 2026. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.625 by $0.175.
Is Cingulate Inc overvalued?
According to Wall Street analysts Cingulate Inc’s price is currently Undervalued.
Does Cingulate Inc pay dividends?
Cingulate Inc does not currently pay dividends.
What is Cingulate Inc’s EPS estimate?
Cingulate Inc’s EPS estimate is -0.43.
How many shares outstanding does Cingulate Inc have?
Cingulate Inc has 14,541,826 shares outstanding.
What happened to Cingulate Inc’s price movement after its last earnings report?
Cingulate Inc reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.625. Following the earnings report the stock price went down -4.223%.
Which hedge fund is a major shareholder of Cingulate Inc?
Hedge funds hold Cingulate Inc shares: the largest hedge-fund position in Cingulate Inc is 71,884,444 shares, and hedge funds increased their holdings by 29.9K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology